Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01601873 · ClinicalTrials.gov registry record · NA
Propaten Randomized Investigation on Cost-benefit and Efficacy
A NA study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- NA
- Development phase
- 103
- Enrollment target
NCT01601873: Clinical Trial NA study, sponsored by The University of Texas Health Science Center, Houston.
NCT01601873 is a NA study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 103 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01601873, a NA study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- NA
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose for this study is to evaluate the patency and outcomes of conventional and heparin anticoagulant bonded arteriovenous grafts in patients with end stage renal disease.
Primary Outcome
Primary graft patency refers to the successful use of a vascular access for hemodialysis without any surgical or endovascular intervention.
Interventions
- DEVICE PROPATEN
- DEVICE Standard Graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2012-11-09 |
| Est. Completion | 2018-06-30 |
| Phase | NA |
Why NCT01601873 stopped before completion
NCT01601873 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which PROPATEN is the first listed.
NCT01601873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01601873 about?
NCT01601873 is a clinical study titled "Propaten Randomized Investigation on Cost-benefit and Efficacy". The purpose for this study is to evaluate the patency and outcomes of conventional and heparin anticoagulant bonded arteriovenous grafts in patients with end stage renal disease.
What is the current status of trial NCT01601873?
This trial is currently terminated. It is a NA study. The enrollment target is 103 participants. The study started on 2012-11-09. Estimated completion is 2018-06-30.
What interventions are being tested in trial NCT01601873?
The interventions under investigation include: PROPATEN (DEVICE), Standard Graft (DEVICE).
Who is sponsoring clinical trial NCT01601873?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01601873's enrollment target sits among peer trials
103 837th of 2000 higher than 1,164 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI